Phage Biotechnology Corp.

News Archives

October 2, 2006, San Diego, CA

Phage moved into a new R&D facility situated approximately 4 miles from the University of California, San Diego campus in La Jolla, CA. The R&D facility is adjacent to Phage’s manufacturing facility which was acquired earlier in the year. The close proximity of the two facilities will permit a better integration of the activities ongoing in each of these important operational areas for Phage.

April 3, 2006, San Diego, CA

Phage has completed the move of its manufacturing activities to a new 7500 square foot facility in the Sorrento Valley area of San Diego. This plant has the capacity to provide Phage and its contract manufacturing clients with lots of material for all anticipated clinical trials over the next 5 year time frame.

January 17, 2006, Las Vegas, NV

Phage today occupied its new corporate headquarters in Las Vegas, Nevada. The company’s chief executives are based there along with corporate administration, legal and human resources. The new office is located in the Summerlin area of Las Vegas and will house additional departments of Phage as the company expands into marketing and sales activities.

November 4, 2005, Irvine, California

Phage Biotechnology is in the process of initiating a Phase II trial to investigate and compare the efficacy of Syntropin™ (a human growth hormone produced by us) and Humatrope ® (somatropin [rDNA origin] for injection, Eli Lilly) in promoting growth in children with idiopathic short stature.

February 2005, Irvine, California

Study results from our Phase I human trial with our human growth hormone product, Syntropin™, demonstrated that it is safe and well-tolerated; there were no significant adverse events in this clinical trial. In addition, the disappearance of Syntropin™ from the circulation of the patients was measured and agreed well with previous results with other marketed growth hormone products.

November 8, 2004, Irvine, California

The U.S. FDA has given permission for Phage to conduct a Phase I human trial with its human growth hormone product, Syntropin™. A twenty patient trial will be carried out in early 2005 at a clinical trial site in Houston, Texas. The safety and clearance of Syntropin™ will be examined and compared to an already marketed growth hormone product.

March 4, 2004, Tustin, California

Phage Biotechnology signed an agreement with a pegylation provider who can pegylate Phage proteins at site-specific sites to create novel and, potentially, more efficacious products. This proprietary process will be applied to Phage's Gentron A (interferon alpha 2b). Published reports have indicated that the two marketed pegylated interferon products lose between 70-90% of their anti-viral activity following pegylation. Site-specific pegylation of Gentron A, leading to enhanced anti-viral activity of Gentron A, could translate into an improved treatment for patients suffering from hepatitis C. Additional animal studies are planned to test the half-life of Peg-Gentron A in the circulation. These two studies will form the basis for an Investigational New Drug (IND) application to the U.S. FDA to test Peg-Gentron A in patients suffering from hepatitis C.

Top